DexCom earnings beat by $0.03, revenue topped estimates
In a recent transaction involving CTT Pharmaceutical (TADAWUL:2070) Holdings, Inc. (OTC:CTTH), CEO Ryan Khouri purchased 11,950 shares of the company. The shares were acquired at a price of $0.09 each, totaling $1,075. The company, currently valued at $3.46 million, has demonstrated strong momentum with a remarkable 136% return over the past year, according to InvestingPro data. This purchase increases Khouri’s direct ownership to 6,569,506 shares. The transaction took place on March 7, 2025, and was disclosed in a filing with the Securities and Exchange Commission. InvestingPro analysis reveals the company maintains a GREAT financial health score, with liquid assets exceeding short-term obligations. Subscribers can access 8 additional key insights about CTTH’s financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.